# Aromasin (Exemestane)

*Also known as: Exemestane, Exe, Suicidal AI*

Steroidal (suicidal) aromatase inhibitor; permanently inactivates aromatase enzyme.

## Overview

Aromasin (exemestane) is a steroidal, irreversible aromatase inhibitor developed for estrogen-receptor-positive breast cancer and used off-label to manage estradiol during testosterone therapy or anabolic cycles. Unlike reversible inhibitors, it is a mechanism-based, or suicidal, inactivator that permanently binds and destroys the aromatase enzyme, so recovery of estradiol requires new enzyme synthesis over several days. The compound has a roughly 23-hour half-life but very low oral bioavailability near 5%, and steady estradiol suppression builds over repeated dosing. Because the enzyme is permanently inactivated, the estradiol fall can overshoot quickly, and the dominant risk is over-suppression, with joint pain, libido loss, lipid deterioration, and mood disturbance when estradiol runs too low. Harm reduction centers on conservative, symptom-driven dosing guided by estradiol bloodwork rather than fixed scheduling, avoiding overlap with other aromatase inhibitors, and retesting promptly if joint or libido symptoms appear.

## Pharmacokinetics

- **Model tier:** advanced
- **Half-life:** 0.9 days (22.699999992000002 hours)
- **Cmax:** 57.6 ng/mL
- **Tmax:** 0.1 days
- **Bioavailability:** 5%

## Dosing

- **Default dose:** 12.5 mg
- **Typical range:** 6.25–25 mg
- **Units:** ng/mL

## Source

- **Label:** PMC exemestane PK
- **URL:** https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884784/

---

**Canonical URL:** https://anabolicdex.com/compounds/aromasin
**Plot:** https://anabolicdex.com/plot?compound=aromasin